Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Odyssey Thera receives US patent for animal imaging
The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at
The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at
The preclinical results demonstrated that ENMD-1198, administered as a single agent, is effective in significantly delaying the growth of leukemia xenografts in vivo. Combination studies with ENMD-1198 and
Ustekinumab is a human monoclonal antibody that binds to the cytokines IL-12 and IL-23 and was generated using Medarex’s UltiMAb technology. Medarex may receive future milestone payments and
The Phase II trial is a double-blind, placebo-controlled trial evaluating 80 high risk geriatric patients following open heart surgery procedures. Patients receive either DCA i.v. or a placebo,
Ongoing pre-clinical studies are being conducted in collaboration with Universite Montpellier in France. These studies on immune-deficient mice are designed to assess and analyze Anavex 7-1037’s ability to
Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a
Houston Pharmaceuticals will continue collaborations with both universities and assist in securing grants on behalf of the company. Leonard Ivins, CEO of Edgeline Holdings, said: “Houston Pharmaceuticals will
In the randomized, international, multicenter, open-label Phase III clinical trial that evaluated the safety and efficacy of bendamustine compared to chlorambucil in previously untreated patients with B- chronic
With this payment, Critical Therapeutics has now received a total of $12 million from Dey as part of the companies’ co-promotion agreement. Critical Therapeutics received $3 million from
The new data showed that the median survival of patients treated with Genasense plus chemotherapy who achieved complete remission (CR, defined as complete plus nodular partial response) has